We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
- Authors
Gold, Michael; Alderton, Claire; Zvartau-Hind, Marina; Egginton, Sally; Saunders, Ann M; Irizarry, Michael; Craft, Suzanne; Landreth, Gary; Linnamägi, Ulla; Sawchak, Sharon
- Abstract
A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR.
- Publication
Dementia and geriatric cognitive disorders, 2010, Vol 30, Issue 2, p131
- ISSN
1421-9824
- Publication type
Journal Article
- DOI
10.1159/000318845